Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Pituitary ACTH Hypersecretion × fimepinostat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pituitary ACTH Hypersecretion 1 Medulloblastoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Glioma 1 Glioblastoma 1 Diffuse Intrinsic Pontine Glioma 1 Astrocytoma 1

Interventions

relacorilant 3 Mifepristone 3 Corlux 3 Cabergoline 3 pasireotide 2 fimepinostat 1 corticorelin ovine 1 Deamino Arginine Vasopressin 1 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05971758 2025-07-04

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

University of California, Los Angeles

Phase 2 Recruiting

Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡